[{"address1": "15 Crosby Drive", "city": "Bedford", "state": "MA", "zip": "01730", "country": "United States", "phone": "781 357 4000", "fax": "781 275 7562", "website": "https://www.ocutx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.", "fullTimeEmployees": 267, "auditRisk": 3, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 6.08, "open": 6.06, "dayLow": 5.96, "dayHigh": 6.26, "regularMarketPreviousClose": 6.08, "regularMarketOpen": 6.06, "regularMarketDayLow": 5.96, "regularMarketDayHigh": 6.26, "beta": 1.415, "forwardPE": -6.188119, "volume": 6988401, "regularMarketVolume": 6988401, "averageVolume": 2527162, "averageVolume10days": 3202420, "averageDailyVolume10Day": 3202420, "bid": 6.24, "ask": 6.27, "bidSize": 200, "askSize": 200, "marketCap": 968056192, "fiftyTwoWeekLow": 1.995, "fiftyTwoWeekHigh": 11.31, "priceToSalesTrailing12Months": 16.1766, "fiftyDayAverage": 5.779, "twoHundredDayAverage": 5.184875, "currency": "USD", "enterpriseValue": 559572736, "profitMargins": -1.92614, "floatShares": 126093517, "sharesOutstanding": 154888992, "sharesShort": 21221363, "sharesShortPriorMonth": 14646476, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.137, "heldPercentInsiders": 0.00784, "heldPercentInstitutions": 0.8058, "shortRatio": 6.32, "shortPercentOfFloat": 0.1376, "impliedSharesOutstanding": 154888992, "bookValue": 2.637, "priceToBook": 2.3701174, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -115266000, "trailingEps": -1.12, "forwardEps": -1.01, "enterpriseToRevenue": 9.351, "enterpriseToEbitda": -6.357, "52WeekChange": 0.31302524, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "OCUL", "underlyingSymbol": "OCUL", "shortName": "Ocular Therapeutix, Inc.", "longName": "Ocular Therapeutix, Inc.", "firstTradeDateEpochUtc": 1406295000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b2e86f5b-6ae3-30af-bdc2-4b9ad5a2cf9e", "messageBoardId": "finmb_41955650", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.25, "targetHighPrice": 22.0, "targetLowPrice": 11.0, "targetMeanPrice": 15.0, "targetMedianPrice": 14.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 482888000, "totalCashPerShare": 3.118, "ebitda": -88030000, "totalDebt": 74405000, "quickRatio": 20.966, "currentRatio": 21.394, "totalRevenue": 59843000, "debtToEquity": 18.237, "revenuePerShare": 0.64, "returnOnAssets": -0.17125, "returnOnEquity": -0.55192, "freeCashflow": -57922376, "operatingCashflow": -84148000, "revenueGrowth": 0.105, "grossMargins": -0.21043, "ebitdaMargins": -1.4710201, "operatingMargins": -2.14004, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]